Provention Bio 2022 Investor Presentation - Teplizumab Autoimmune

Provention Bio presents its pipeline of immunotherapy candidates focused on early intervention in autoimmune diseases to prevent irreversible tissue damage. The presentation covers teplizumab's regulatory pathway, commercial opportunity among 23+ million US autoimmune patients, and the company's strategy to intercept disease before late-stage complications emerge.